Brittany A McKelvey, Hillary S Andrews, Frederick L Baehner, James Chen, Carin R Espenschied, David Fabrizio, Vanessa Gorton, Claire Gould, Justin Guinney, Greg Jones, Xiangyang Lv, Michael S Nahorski, Melanie R Palomares, Gary A Pestano, Mark Sausen, Alain Silk, Nicole Zhang, Zhihong Zhang, Mark D Stewart, Jeff D Allen
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development. However, the heterogeneity in ctDNA levels prior to treatment (baseline) across different cancer types and stages and across ctDNA assays has not been widely studied. Friends of Cancer Research formed a collaboration across multiple commercial ctDNA assay developers to assess baseline ctDNA levels across five cancer types in early- and late-stage disease...
April 27, 2024: Diagnostics